FK037, a new parenteral cephalosporin, is an oxime-type cephem antibiotic with a 1-hydroxyethyl-5-aminopyrazole moiety at the 3 position. FK037 was evaluated for antimicrobial activity in vitro and in vivo. In vitro, FK037 was twofold or more active than ceftazidime, cefoperazone, cefotaxime, and ceftriaxone against Pseudomonas aeruginosa (MIC for 90%o of the strains [MIC.] = 32 ,ug/ml), members of the family Enterobacteriaceae (MIC90 5 2 ,ug/ml), group A streptococci (MIC9 0.015 ,g/ml), and methicillin-sensitive or -resistant coagulase-negative staphylococci (MIC90 = 2 and 16 ,ug/ml, respectively). In addition, the activity of FK037 was equal to or greater than that of ceftazidime, cefotaxime, or ceftriaxone against Streptococcus pneumoniae (MIC90 = 0.12 .g/ml) and methicillin-sensitive or -resistant Staphylococcus aureus (MIC90 = 2 and 16 ug/ml, respectively). FK037 was more active in vitro than cefepime (two-to fourfold) and cefpirome (twofold) against S. aureus. In murine systemic infection models, FK037 showed potent activity against P. aeruginosa, Escherichia coli, and methicillin-sensitive and methicillin-resistant S. aureus. FK037 was also efficacious in a mouse model of pyelonephritis caused by S. aureus or KlebsieUla pneumoniae and in a mouse model of pneumococcal pneumonia caused by S. pneumoniae. Additional studies on this compound to assess its potential clinical utility are warranted.
potential clinical utility are warranted.
Cephalosporins are very important in the treatment of bacterial infections because they exhibit broad antibacterial activities, have little toxicity, and are generally well tolerated (1) . Structural modifications of the cephem nucleus have produced a variety of antimicrobial agents with improved, broad spectra of activity and ,-lactamase stability (8, 14) . FK037 ( . Preliminary studies showed that FK037 exhibits potent in vitro and in vivo antibacterial activities (11, 15) in addition to its ,B-lactamase stability (6) . In this study, we compared the in vitro and in vivo activities of FK037 with those of the more recently developed cephalosporins, including cefepime and cefpirome.
MATERIALS AND METHODS Antimicrobial agents. The antibiotics used in this study were FK037 (Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan), ceftazidime (Lilly), cefepime (Bristol-Myers Squibb), cefpirome (Hoechst), imipenem (Merck), and ofloxacin (Ortho Pharmaceutical Corp.). Gentamicin, phosphomycin, cefotaxime, ceftriaxone, cefoperazone, and penicillin G were purchased from Sigma Chemical Co., St. Louis, Mo.
Bacterial strains. Clinical isolates including P-lactamaseproducing organisms were obtained from several hospitals during 1989 to 1992 and were maintained at -70°C in our laboratory.
Susceptibility testing. MICs were determined according to agar dilution methods outlined by the National Committee for Clinical Laboratory Standards (NCCLS) (13) . A check-* Corresponding author. erboard agar dilution method was used to evaluate the interaction of combined drugs. Synergy was determined by using the fractional inhibitory concentration index (9).
Bactericidal activity. The MBCs of FK037 and ceftazidime were determined by a broth microdilution method (12) . Compounds were serially diluted in Mueller-Hinton broth (MHB) cation supplemented as described by NCCLS. After incubation, negative broths were subcultured onto blood agar to determine the MBC. The lowest concentration of FK037 that exhibited 99.9% reduction of the numbers of colonies compared with the CFU in the initial inoculum was considered the MBC.
Time-kill study. FK037 at two-and fourfold the MICs against Staphylococcus aureus OC2069 and Pseudomonas aeruginosa OC43 was tested in a time-kill study. Test organisms were grown overnight, diluted to 1 x 106 to 3 x 106 CFU/ml. One milliliter of this was added to MHB with and without FK037, resulting in a final inoculum of 3.5 x 105 CFU/ml. At 
RESULTS
Antibacterial activity against clinical isolates. In vitro, FK037 was two-to fourfold more active than ceftazidime, cefoperazone, cefotaxime, and ceftriaxone against Pseudomonas spp., most of the members of the family Enterobacteriaceae, group A, B, and C streptococci, and the coagulase-negative staphylococci (Table 1) . FK037 had activity equal to or greater than that of ceftazidime, cefotaxime, or ceftriaxone against S. pneumoniae (MIC for 90% of strains tested [MIC90 = 0.12 j±g/ml) and both MRSA and MSSA (MIC90s = 16 and 2 ,ug/ml, respectively). Sixteen of the 47 MRSA strains tested demonstrated high degrees of methicillin resistance (MIC 128 ,ug/ml). The MIC90s for FK037 against low-and high-methicillin-resistant strains were 8 and 32 ,ug/ml, respectively. FK037 was equipotent with cefpirome against staphylococci except for MRSA and more potent against these organisms than cefepime. FK037 was equipotent with cefepime and cefpirome against P. aeruginosa. Against ciprofloxacin-resistant coagulase-negative staphylococci, the MIC of FK037 was 4 ,ug/ml. The clinical relevance of these MRSA data is unknown because these studies were not performed under conditions maximizing methicillin resistance.
FK037 was less potent than either cefotaxime or ceftriaxone against Haemophilus influenzae and Neisseria gonorrhoeae; however, the concentration attained for FK037 in serum is severalfold greater than the MIC90s of FK037 (0.015 to 0.25 ,ug/ml) against these organisms (5). FK037 was more potent than imipenem against MRSA, some members of the family Enterobacteriaceae, H. influenzae, and N. gonorrhoeae but was less potent than imipenem against Pseudomonas spp., MSSA, and group A, B, and C streptococci ( Table 1) .
MICs and MBCs for FK037 (data not shown) were equivalent when the compound was tested against staphylococci and members of the family Enterobacteriaceae, while the MBC was fourfold higher for the Pseudomonas spp. Results of an inoculum size study showed that both the MICs and MBCs for gram-negative organisms were increased because of inoculum size while only the MBC for the staphylococci increased at the highest level (data not shown). Time-kill tests (Fig. 2 ) also showed that FK037 was rapidly bactericidal against S. aureus and P. aeruginosa for the first 6 h at two and four times the MIC of FK037, respectively. However, regrowth at the 24-h incubation sample time was noted. The postantibiotic effects for FK037 against S. aureus at two and four times the MIC were 1 and 1.2 h, respectively.
The study of the interaction of FK037 with ofloxacin demonstrated that the combination was synergistic for 14% of the P. aeruginosa strains and synergistic for 8% of the MSSA strains (Table 2) . When FK037 was combined with gentamicin, the results were 36% synergistic for P. aeruginosa and 22% synergistic for Enterobacter cloacae. When FK037 was tested for interaction with phosphomycin, an antibiotic that is an inhibitor of pyruvyl transferase, which is essential to cell wall synthesis in bacteria, the combination was synergistic against 35% of Pseudomonas strains and 92% of the MRSA strains. They were also synergistic against 25 to 33% of the other staphylococci. No antagonism occurred with any combination of compounds and FK037 against any of the organisms tested.
As shown in Table 3 , the frequency of resistance of MSSA to FK037 after exposure to two-, four-, and eightfold the MIC of FK037 was very low (<2 x 10-9). For imipenem, the development of resistance showed a wider range (8.7 x 10' and <2 x 10-9) than that for FK037. Against MRSA OC641, however, the frequency of resistance to FK037 developed at fourfold the MIC was 4.2 x 10' but was not detectable at eightfold the MIC. Resistance to imipenem developed even at eightfold the MIC (2.4 x 10-5). Against MRSA OC667 at four-and eightfold the MIC of FK037, the MIC resistance frequency was low (2 x 10-9), and that with imipenem was above the detectable limits of the experiments.
In vivo infection models. The efficacy of FK037 in acute systemic infections in mice is shown in Table 4 . FK037 was equipotent to ceftazidime against two Pseudomonas strains tested and equipotent to ceftriaxone against one of the Pseudomonas strains. Against a systemic E. coli infection, FK037 was equipotent to ceftazidime and ceftriaxone. Against MRSA, FK037 was twofold more potent than either ceftriaxone or ceftazidime. For the MSSA, the 50% effective their resistance to P-lactamase hydrolysis (7) and their ability to penetrate the outer cell envelope of gram-negative bacilli (14) . Our data demonstrated that FK037 showed potent in vitro activity against a broad spectrum of grampositive and gram-negative organisms. FK037 showed potent activity against ,B-lactamase-producing bacteria resistant to cefoperazone and ceftazidime. The study showed that FK037 has a broader spectrum of activity, especially against gram-positive organisms, than ceftazidime and ceftriaxone. FK037 was more active against S. pneumoniae and MRSA than currently available cephalosporins. A major advantage for FK037 may be its activity against MRSA and Pseudomonas spp., because more recently available cephalosporins have poor activity against these organisms. These data have shown that FK037 has a broader'spectrum of antibacterial activity than ceftazidime and ceftriaxone. Additional studies on FK037 to assess its clinical utility are warranted.
